This news is delayed by 15 minutes, sign up now to get live news & full features.
VERA VERA THERAPEUTICS INC
+ add to watchlist
$24.24
trucode gene repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. the elegance of triplex gene editing lies in its ability to harness natural, high-fidelity dna repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors.
Mkt Cap: $1.55B
52 Week High: $51.61
P/E: 0.00
52 Week Low: $18.53
Dividend: $0.00
Shares Outstanding: 63.77M